Related Experiment Video
Updated: Oct 24, 2025
Osteoarthritis Pain Model Induced by Intra-Articular Injection of Mono-Iodoacetate in Rats
Published on: May 20, 2020
[Effect of rebamipide on the acute gouty arthritis in rats induced by monosodium urate crystals]
1Department of Rheumatology and Immunology, Anqing Hospital of Anhui Medical University, Anqing 246000, Anhui, China.
Objective:
To investigate the role of rebamipide in the treatment of acute gout arthritis rats induced by monosodium urate (MSU) crystal.
Methods:
Forty-two male rats were randomly divided into three groups (n=14). Group A was treated with oral rebamipide, group B with oral colchicine, and group C with oral placebo. The rats were monitored for the induction of arthritis with clinical manifestations and pathological changes, and the levels of interleukin (IL)-1β、IL-6、IL-10, and tumor necrosis factor (TNF)-α in serum were measured.
Results:
In group C, the clinical score and swelling index reached the maximum in 24 h, and then gradually decreased to 72 h. After 24 h of model induced, the clinical scores in group C were significantly higher than those in group A and group B [2 (1-3) vs. 0 (0-1) vs. 1 (0-2), P < 0.01], the swelling indexes in group C were significantly higher than those in group A and group B [0.36 (0.16-0.52) vs. 0.11 (0-0.20) vs. 0.12 (0-0.16), P < 0.01]. Histologically, after 24 h of model induced, there was a large number of neutrophil infiltration in the synovium of group C [scale score: 4 (2-4)], and there was no significant inflammatory cell infiltration in group A [1 (0-2)] and group B [1 (0-2)], the difference was statistically significant (P < 0.001). After 24 h of model induced, the levels of IL-1β, IL-6, IL-10, and TNF-α in serum of group C were significantly higher than those in group A and B [IL-1β: (41.86±5.72) vs. (27.35±7.47) vs. (27.76±5.28) ng/L, IL-6: (1 575.55±167.11) vs. (963.53±90.22) vs. (964.08±99.31) ng/L, IL-10: (37.96±3.76) vs. (21.68±4.83) vs. (16.20±2.49) ng/L, TNF-α: (21.32±1.34) vs. (15.82±2.54) vs. (17.35±7.47) μg/L, P < 0.001].
Conclusion:
Rebamipide has a protective effect on acute gout arthritis rats induced by MUS crystals.
Insights
Rebamipide demonstrates a protective effect against acute gout arthritis in rats induced by monosodium urate (MSU) crystals. This study found rebamipide significantly reduced clinical scores and inflammatory markers compared to placebo.
Area of Science:
- Pharmacology
- Immunology
- Rheumatology
Background:
- Gout arthritis is an inflammatory condition caused by monosodium urate (MSU) crystal deposition.
- Current treatments aim to reduce inflammation and pain, but novel therapeutic agents are continually sought.
Purpose of the Study:
- To evaluate the therapeutic potential of rebamipide in an animal model of acute gout arthritis.
- To assess the impact of rebamipide on clinical and pathological indicators of inflammation.
Main Methods:
- Acute gout arthritis was induced in male rats using MSU crystals.
- Rats were randomized into three groups: rebamipide, colchicine (positive control), and placebo.
- Clinical scores, swelling indexes, synovial infiltration, and serum levels of IL-1β, IL-6, IL-10, and TNF-α were measured.
Main Results:
- Rebamipide treatment significantly reduced clinical scores and swelling indexes compared to placebo (P < 0.01).
- Histological analysis showed markedly reduced neutrophil infiltration in the synovium of rebamipide-treated rats (P < 0.001).
- Serum levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and IL-10 were significantly lower in the rebamipide group compared to placebo (P < 0.001).
Conclusions:
- Rebamipide exhibits significant protective effects against acute MSU crystal-induced gout arthritis in rats.
- Rebamipide may serve as a potential therapeutic agent for managing gouty arthritis by modulating inflammatory responses.
